TN-001

TN-001 is a novel, non-hallucinogenic neuroplastogen developed for the treatment of neuropsychiatric and neurodegenerative disorders. It is designed to engage serotonergic receptors implicated in therapeutic effects for these conditions, aiming to provide the efficacy associated with psychedelic drugs but without hallucinogenic side effects. This allows for traditional dosing and eliminates the need for intensive clinical supervision. TN-001 represents a first-in-class approach targeting improved safety, ease of administration, and superior efficacy compared to current standard-of-care therapies in neuropsychiatric disorders[1].